BAYRY:OTO-Bayer AG ADR (Sponsored) (USD)

COMMON STOCK | Drug Manufacturers—General | OTC Pink

Last Closing

USD 15.36

Change

-0.12 (-0.78)%

Market Cap

USD 92.32B

Volume

0.57M

Analyst Target

USD 26.10
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Bayer AG is engaged in the development, production and marketing of prescription Pharmaceutical. Its business segments are pharmaceutical, Consumer Health, Crop Science, Animal Health, and Covestro.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-04-08 )

Largest Industry Peers for Drug Manufacturers—General

ETFs Containing BAYRY

SMTU:PA 7.18 % 0.00 %

N/A

N/A
SMTU:XETRA 7.18 % 0.00 %

N/A

N/A
INAG 2.93 % 0.00 %

N/A

N/A
TWAR 1.29 % 0.00 %

N/A

N/A
UEFR:F 0.61 % 0.00 %

N/A

N/A
UEFR:XETRA 0.61 % 0.00 %

N/A

N/A
DBGR 0.00 % 0.46 %

N/A

N/A
DXGE 0.00 % 0.48 %

N/A

N/A
EWG iShares MSCI Germany ETF 0.00 % 0.47 %

-0.12 (0.35%)

USD 0.03B
HEWG iShares Currency Hedged M.. 0.00 % 0.06 %

-0.04 (0.35%)

USD 0.03B
FLGR Franklin FTSE Germany ETF 0.00 % 0.09 %

-0.04 (0.35%)

USD 0.02B
IEDL:LSE iShares Edge MSCI Europe .. 0.00 % 0.00 %

+0.02 (+0.35%)

USD 1.70B
IEFV:LSE iShares MSCI Europe Value.. 0.00 % 0.00 %

+0.55 (+0.35%)

USD 1.54B
IEVL:LSE iShares MSCI Europe Value.. 0.00 % 0.00 %

+0.02 (+0.35%)

USD 1.54B
CG1:PA Amundi ETF DAX UCITS ETF .. 0.00 % 0.00 %

+0.25 (+0.35%)

USD 0.60B
DAX:PA Multi Units Luxembourg - .. 0.00 % 0.00 %

+0.18 (+0.35%)

USD 0.71B
MIVU:PA Amundi Index Solutions MS.. 0.00 % 0.00 %

+0.88 (+0.35%)

USD 0.30B
C001:XETRA Lyxor Core DAX (DR) UCITS.. 0.00 % 0.00 %

+0.06 (+0.35%)

USD 1.06B
C006:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

+0.01 (+0.35%)

USD 0.09B
DBXD:XETRA Xtrackers - DAX UCITS ETF 0.00 % 0.00 %

+0.10 (+0.35%)

USD 4.11B
EL4A:XETRA Deka DAX UCITS ETF 0.00 % 0.00 %

+0.14 (+0.35%)

USD 1.21B
EL4F:XETRA Deka DAX (ausschüttend) .. 0.00 % 0.00 %

+0.02 (+0.35%)

USD 0.79B
MIVU:XETRA Amundi Index Solutions MS.. 0.00 % 0.00 %

+0.83 (+0.35%)

USD 0.38B
XDDX:XETRA Xtrackers DAX Income UCIT.. 0.00 % 0.00 %

+0.12 (+0.35%)

USD 0.29B
EXS1:XETRA iShares Core DAX® UCITS .. 0.00 % 0.00 %

+0.14 (+0.35%)

USD 5.83B
E909:XETRA Lyxor 1 DAX 50 ESG (DR) U.. 0.00 % 0.00 %

+0.14 (+0.35%)

USD 0.26B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers—General) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.26% 26% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.26% 26% F 50% F
Trailing 12 Months  
Capital Gain -10.02% 40% F 69% C-
Dividend Return 3.23% 69% C- 59% D-
Total Return -6.79% 37% F 69% C-
Trailing 5 Years  
Capital Gain -59.50% 17% F 36% F
Dividend Return 8.03% 55% F 40% F
Total Return -51.48% 17% F 37% F
Average Annual (5 Year Horizon)  
Capital Gain -10.71% 11% F 20% F
Dividend Return -8.39% 11% F 21% F
Total Return 2.33% 65% D 56% F
Risk Return Profile  
Volatility (Standard Deviation) 24.41% 39% F 69% C-
Risk Adjusted Return -34.35% 17% F 20% F
Market Capitalization 92.32B 74% C 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector